8-K: Seer Inc. Reports Q1 2024 Results with Revenue Decline but Strategic Expansion

Seer Inc. announced a 24% decrease in revenue for Q1 2024 compared to the previous year, alongside the expansion of its technology access program into Europe and a share repurchase program.

Summary

• Seer Inc. reported a revenue of $3.1 million for the first quarter of 2024, which is a 24% decrease compared to $4.1 million in the same period last year.
• This decrease is primarily attributed to a reduction in product and related party revenue.
• Product revenue was $2.5 million, including $828 thousand from related parties, while service revenue was $534 thousand, including $126 thousand from related parties.
• The company's gross profit was $1.4 million with a gross margin of 44%.
• Operating expenses decreased by 10% to $26.6 million, driven by lower employee and stock-based compensation and laboratory expenses.
• Seer's net loss for the quarter was $20.7 million, an improvement from the $24.0 million loss in the same quarter of the previous year.
• The company ended the quarter with $359.2 million in cash, cash equivalents, and investments.
• Seer has authorized a share repurchase program of up to $25 million.
• Full year 2024 revenue is expected to be in the range of $16 million to $18 million, consistent with 2023 revenue.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the significant revenue decline, despite some positive developments like cost control and strategic expansion. The company is still operating at a loss and faces challenges in commercial adoption.

Positives

• Operating expenses decreased by 10%, indicating cost management efforts.
• Net loss improved compared to the same quarter last year.
• The company has a strong cash position of $359.2 million.
• The expansion of the STAC program to Europe increases market reach.
• The share repurchase program could boost investor confidence.
• The launch of the 2024 Seer Insights Grant Program will increase accessibility to their technology.
• The company has seen three peer-reviewed publications this year, validating their technology.

Negatives

• Revenue decreased by 24% year-over-year, primarily due to a decline in product and related party revenue.
• Product revenue was $2.5 million, including $828 thousand of related party revenue, indicating a reliance on related party transactions.
• Service revenue was $534 thousand, including $126 thousand of related party revenue, also indicating a reliance on related party transactions.
• The company is still operating at a net loss of $20.7 million for the quarter.

Risks

• The company is experiencing continued headwinds in the commercial adoption of its technology.
• The decrease in revenue, particularly in product sales, could indicate challenges in market penetration.
• The reliance on related party revenue could pose a risk if those relationships change.
• The company is still operating at a loss, which could impact long-term sustainability.

Future Outlook

Seer expects full year 2024 revenue to be in the range of $16 million to $18 million, which is in line with full year 2023 revenue.

Management Comments

• Omid Farokhzad, Chair and CEO of Seer, stated that they are committed to reducing barriers to commercial adoption of their technology despite headwinds.
• He also mentioned that they are focusing resources on commercial reach while preserving their balance sheet.
• He expressed excitement about expanding the STAC program into Europe and remains bullish on the potential of their technology.

Industry Context

Seer operates in the competitive life sciences and proteomics sector, where companies are constantly innovating to provide better tools for research and drug discovery. The expansion of the STAC program and the publication of peer-reviewed papers are positive steps for the company in this context.

Comparison to Industry Standards

• Seer's revenue decline of 24% year-over-year is concerning, especially when compared to other life science companies that are experiencing growth.
• Companies like Illumina and Thermo Fisher Scientific, while operating at a larger scale, have shown more consistent revenue growth in their respective sectors.
• The gross margin of 44% is reasonable for a company in the early stages of commercialization, but it needs to improve to be competitive with established players.
• The decrease in operating expenses is a positive sign, but the company needs to demonstrate a clear path to profitability.
• The share repurchase program is a positive move, but it may not be enough to offset the negative impact of the revenue decline.

Related Party Transactions

• Product revenue included $828 thousand from related parties.
• Service revenue included $126 thousand from related parties.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline, but the share repurchase program could provide some support.
• Employees may be affected by cost-cutting measures, but the company is still investing in growth.
• Customers will benefit from the expansion of the STAC program and the grant program.
• Suppliers may see a decrease in orders due to the revenue decline.

Next Steps

• Seer will continue to focus on commercial reach and reducing barriers to adoption of their technology.
• The company will expand the STAC program in Europe.
• Seer will continue to support research through the 2024 Seer Insights Grant Program.
• The company will execute the share repurchase program.

Key Dates

Keywords

Proteomics, Proteograph, Life Sciences, Revenue, Share Repurchase, STAC, Financial Results, Biotechnology, Research, Grants